72
Participants
Start Date
July 31, 2026
Primary Completion Date
July 31, 2031
Study Completion Date
July 31, 2031
Indomethacin
"Indomethacin is a nonsteroidal anti-inflammatory. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation.~Indomethacin (1.5 mg/kg) will be taken orally prior to one MRI study visit."
Placebo
Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit.
MRI
CBF testing will be performed on 3T MRI scanners (GE Healthcare)
National Institutes of Health (NIH)
NIH
University of Wisconsin, Madison
OTHER